The National Stock Exchange has announced significant revisions to its Nifty indices following the J.B. Chemicals & Pharmaceuticals removal due to its merger with Torrent Pharma. According to reports from Business Standard, Prime Focus will replace J.B. Chemicals & Pharmaceuticals across multiple indices including the Nifty 500, Nifty Smallcap 250, Nifty MidSmallcap 400, Nifty Total Market, Nifty Smallcap 500 and Nifty Pharma. The replacement extends to various sub-indices such as the Nifty500 Equal Weight, Nifty500 Multicap 50:25:25, and Nifty500 LargeMidSmall Equal-Cap Weighted indices.
In the Nifty Microcap 250, Prime Focus will be excluded and replaced by Grindwell Norton. As reported by Business Standard, Grindwell Norton will also be added to the Nifty Total Market index in place of J.B. Chemicals & Pharmaceuticals, while Ratnamani Metals & Tubes will replace the company in the Nifty Smallcap 500. In the Nifty Pharma index, Sai Life Sciences will replace J.B. Chemicals & Pharmaceuticals, though no replacement will be made in the Nifty500 Healthcare index following the exclusion.
According to Business Standard, other significant changes include Force Motors joining the Nifty500 Multicap India Manufacturing 50:30:20, Acutaas Chemicals entering the Nifty MidSmall Healthcare, and Indian Energy Exchange (IEX) replacing J.B. Chemicals & Pharmaceuticals in the Nifty Smallcap250 Quality 50. Saregama India will replace J.B. Chemicals & Pharmaceuticals in the Nifty MidSmallcap400 Momentum Quality 100, while Caplin Point Laboratories will be added to both the Nifty500 Multicap Momentum Quality 50 and Nifty Total Market Momentum Quality 50 indices.
As reported by Business Standard, NTPC will replace J.B. Chemicals & Pharmaceuticals in the Nifty500 Low Volatility 50, while ITC will enter the Nifty500 Multifactor MQVLv 50. Zydus Wellness will be included in the Nifty Smallcap250 Momentum Quality 100. Additionally, J.B. Chemicals & Pharmaceuticals will be removed from the Nifty500 Shariah index with no replacement being included. The comprehensive revisions reflect the market impact of the J.B. Chemicals-Torrent Pharma merger across multiple market capitalization segments.
